|
|
Omega Funds was established in 2004, and manages six funds with investments across Europe, North America and the Far East. Omega invests in both public and private companies, completing investments across all healthcare sectors, including biotech, medtech, diagnostics, services and healthcare IT since inception. The firm considers investments in three areas: Primary Venture -- Investing in early-, mid- and late-stage private companies developing transformational technologies and products to address unmet needs in healthcare and biotechnology; Publics -- Supporting the capital needs of publicly traded, small-cap life sciences companies with short or medium term clinical milestones, usually via PIPEs or IPOs; and Direct Secondaries -- Providing partial or total liquidity as well as follow-on capital, to existing shareholders in single assets or portfolios of companies. Investments have led to 52 new products, many charting new treatment courses for patients with devastating diseases such as acute lymphoblastic leukemia, melanoma, and Huntington's disease, among many others.
|
